

Title: Achieving Optimal Patient Outcomes in Renal Cell Carcinoma: Translating Evidence Into Clinical Practice

Dates: January 14, 2016 – May 17, 2016

Locations: Regional Meeting Series

Learning Objectives:

- Recognize factors that may place patients at risk for TLS including type of malignancy and new and emerging cancer therapies
- Identify patients at risk for TLS who would benefit from close monitoring and prophylactic measures
- Apply appropriate preventative and treatment strategies for hyperuricemia and TLS in cancer patients.

Target Audience: This activity is designed for medical oncologists, urologists, genitourinary oncologists, oncology nurses, and other healthcare professionals involved in the care and treatment of patients with advanced RCC.

Program Overview: The American Cancer Society estimates that there will be 61,560 new cases of kidney cancer in 2015, with approximately 14,080 deaths (American Cancer Society, 2015). Targeted therapy using tyrosine kinase inhibitors (TKIs), anti-vascular endothelial growth factor (VEGF) antibodies, and mechanistic target of rapamycin (mTOR) inhibitors is widely used in first- and second-line treatment of advanced or metastatic RCC. Multiple agents have been approved by the US Food and Drug Administration (FDA) for the treatment of advanced or metastatic RCC, and several investigational therapies are in development. This activity will address educational gaps related to the treatment and management of RCC and provide strategies to integrate FDA-approved agents into clinical practice to aid clinicians with the selection of optimal treatment.

Faculty:

Brian I. Rini, MD, FACP
Professor of Medicine
Lerner College of Medicine
Leader, GU Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation



requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and AXIS Medical Education. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement:

Clinical and Patient Educators Association designates this enduring activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support: This activity is supported by independent educational grants from Novartis Pharmaceuticals and Prometheus Laboratories Inc.

